Keyphrases
Acute Myeloid Leukemia
22%
ADAMTS13
34%
ADAMTS13 Protein
45%
Adult Patients
100%
Alternative Complement Pathway
45%
Anticoagulation
63%
Arthrocentesis
45%
Bleeding
24%
Bleeding Risk
60%
Care Pathway
45%
Cerebral Infarction
45%
Cognitive Impairment
38%
Comparative Analysis
45%
Confidence Interval
25%
Consensus Statement
45%
Continuous Infusion
45%
COVID-19
45%
Critically Ill Patients
45%
Cryptogenic Stroke
45%
Deferasirox
45%
Differential Diagnosis
18%
Direct Oral Anticoagulants
45%
Emicizumab
45%
Fanconi Syndrome
45%
FLLL32
45%
Hematological Abnormalities
22%
Hematological Parameters
45%
Immune Thrombocytopenic Purpura
37%
Joint Aspiration
27%
Joint Injection
45%
Mayo Clinic
54%
Microangiopathic Hemolytic Anemia
31%
Myeloid Sarcoma
45%
Oxidative Hemolysis
45%
Recurrent Stroke
22%
Remission
45%
Retrospective Cohort Study
45%
Silent Cerebral Infarction
45%
Survival Analysis
45%
Survivors
19%
Thrombocytopenia
20%
Thrombosis with Thrombocytopenia Syndrome
45%
Thrombotic Microangiopathy
45%
Thrombotic Thrombocytopenic Purpura
34%
Transfusional Iron Overload
45%
Type 3 Von Willebrand Disease
45%
Viral Illness
20%
Von Willebrand Disease
45%
Von Willebrand Factor
29%
Von Willebrand Factor Concentrate
51%
Medicine and Dentistry
3 (6 Bromo 2 Pyridinyl) 2 Cyano N (1 Phenylethyl)acrylamide
11%
Acute Myeloid Leukemia
22%
Anticoagulation
72%
Apoplexy
45%
Arthrocentesis
45%
Bleeding
63%
Brain Infarction
45%
Care Pathway
45%
Ciclonicate
12%
Clinical Pathway
11%
Complement Alternative Pathway
45%
Continuous Infusion
45%
COVID-19
90%
COVID-19 Vaccination
15%
COVID-19 Vaccine
20%
COVID-19 Vaccine Janssen
10%
Deferasirox
45%
Diagnostic Test
11%
Differential Diagnosis
22%
Direct Oral Anticoagulant
45%
Disease
53%
Drug Therapy
18%
Emicizumab
45%
Fanconi Syndrome
45%
Glucose-6-Phosphate Dehydrogenase Deficiency
45%
Hazard Ratio
12%
Immunoglobulin
13%
Intensive Care Unit
21%
Iron Overload
45%
Ischemia
11%
Joint Aspiration
27%
Joint Injection
45%
Major Bleeding
12%
Methemoglobinemia
45%
Microangiopathy
96%
Monoclonal Gammopathy of Undetermined Significance
13%
Myeloid Sarcoma
45%
Nitric Oxide
45%
Outpatient
14%
Platelet
14%
Proteasome Inhibitor
45%
Retrospective Cohort Study
45%
Thrombocytopenia
68%
Thrombosis
56%
Thrombotic Thrombocytopenic Purpura
79%
Tubular Dysfunction
11%
Viral Disease
20%
Von Willebrand Disease
90%
Von Willebrand Factor
58%
Von Willebrand Factor Cleaving Proteinase
49%
Pharmacology, Toxicology and Pharmaceutical Science
3 (6 Bromo 2 Pyridinyl) 2 Cyano N (1 Phenylethyl)acrylamide
9%
Adult Respiratory Distress Syndrome
9%
Adverse Event
10%
Alloantibody
6%
Anemia
9%
Antiplatelet
5%
Bite
9%
Bleeding Disorder
6%
Blister
9%
Brain Ischemia
5%
Calcium Ion
5%
Cerebral Sinus Thrombosis
5%
Ciclonicate
12%
COVID-19 Vaccine
25%
Emicizumab
45%
Enzyme-Linked Immunosorbent Assay
5%
Epileptic Absence
6%
Glucose 6 Phosphate Dehydrogenase Deficiency
45%
Haemophilia A
6%
Heart Infarction
5%
Heart Right Ventricle Failure
9%
Hemolytic Anemia
9%
Heparin Induced Thrombocytopenia
10%
Immunoglobulin
13%
Intubation
9%
Lung Embolism
5%
Methemoglobinemia
45%
Metrorrhagia
6%
Microangiopathy
45%
Monoclonal Immunoglobulinemia
13%
Nitric Oxide
45%
Proteasome Inhibitor
45%
Syndrome
45%
Thrombocytopenia
45%
Thrombosis
45%
Vaccination Policy
45%
Vein Embolism
5%
Von Willebrand Disease
90%
Von Willebrand Factor
58%
